Gambling with biochips
The monopoly held by the large pharmaceutical companies within drug discovery could be falling into the hands of biotechnology firms claims Frost and Sullivan.
Biotechnology is taking over the pharmaceutical stronghold
The monopoly held by the large pharmaceutical companies within drug discovery could be falling into the hands of biotechnology firms claims Frost and Sullivan. The consultancy company's report, Biochips Technology Redefines Process of Drug Discovery, states that biochip manufacturers are encouraging end users to accept the new technology by providing novel and effective solutions.
In return for the offers provided by the biochip manufacturers, drug discovery companies are slowly incorporating the technology into the product pipeline, which is aimed at reducing timelines and attrition rates. Drug targets can be identified and prioritized quickly with the technology because biochips have the ability to confirm several gene expressions at the same time.
However, the innovative nature of the technology is not enough to cause widespread uptake, which is currently slowed by the cost. Potential customers are unsure if the benefits outweigh the initial price. Nevertheless, this market is predicted to grow by 25% from 2004–2011, with higher growth expected in the protein section because of the nature of drug targets.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
